Vyleesi (Bremelanotide) Switching Reports: What Patients Actually Experience

What Is Bremelanotide and How Was It Approved?

Bremelanotide targets melanocortin receptors in the central nervous system, a mechanism distinct from every other sexual medicine agent on the market. The FDA granted approval on August 23, 2019, based primarily on the two parallel RECONNECT phase 3 trials published in Obstetrics and Gynecology. Unlike flibanserin, which requires daily dosing, bremelanotide is taken as needed, up to 45 minutes before anticipated sexual activity.

The RECONNECT Trial Numbers

The RECONNECT program enrolled 1,267 premenopausal women across two replicate trials. In RECONNECT, bremelanotide produced a statistically significant improvement on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) score compared with placebo, with approximately 25% of bremelanotide-treated participants meeting the responder threshold versus 17% on placebo [1]. That 8-percentage-point absolute difference is real but modest. Patients and prescribers both need to understand this before starting.

The FDA label for bremelanotide specifies that the drug is not intended for use in postmenopausal women or in men, and it carries a contraindication in patients with known cardiovascular disease because of its transient blood pressure effects [2].

Mechanism: Why It Works Differently From Flibanserin

Flibanserin acts on serotonin and dopamine receptors after weeks of daily dosing. Bremelanotide bypasses that pathway entirely. It binds MC4R receptors in the hypothalamus, a region tied to sexual motivation in animal and early human neuroimaging research reviewed in [3]. The on-demand pharmacokinetics mean peak plasma concentration arrives within about 1 hour of injection, and the drug is largely cleared within 12 hours [2].

What Real Patients Report: Reddit, Drugs.com, and PatientsLikeMe

Patient-reported experiences online divide into three roughly equal clusters: strong responders who call bremelanotide life-changing, non-responders who feel nothing beyond the side effects, and a middle group who quit after the nausea.

Positive Switching Reports

On r/TwoXChromosomes and several HSDD-focused threads on Reddit, users who switched to bremelanotide after failing flibanserin describe a qualitatively different experience. The most common positive framing is that bremelanotide produces a sense of anticipation or warmth within 30-45 minutes of injection that flibanserin never generated even after months of daily use. One frequently cited comment describes the feeling as "like my body remembered something it had forgotten," with the poster noting she had been on flibanserin for 11 months without benefit before switching.

Drugs.com hosts over 60 user reviews for bremelanotide as of early 2025. The mean rating sits at approximately 6.2 out of 10. Reviewers who rate it 8 or higher almost uniformly mention the on-demand nature as the deciding factor. They report preferring a single injection before intimacy to a daily pill that requires abstaining from alcohol.

Negative and Mixed Reports

The most common complaint, mirroring the 40% nausea rate in RECONNECT [1], is that the side effect window (typically 30-90 minutes post-injection) overlaps directly with the intended window of sexual activity. Several users on PatientsLikeMe describe injecting, feeling nauseated and flushed, and abandoning the plan entirely. One Drugs.com review summarizes it plainly: "The nausea makes intimacy impossible, which defeats the entire point."

Flushing (reported in approximately 20% of RECONNECT participants [1]) and mild headache (11%) are the next most cited complaints. Hyperpigmentation of the face, gums, or breasts is rare but documented; the FDA label warns that patients with dark skin tones or those prone to melasma may be at higher risk [2].

What the Selection Bias Means for These Reports

Online reviews overrepresent outliers. Strong responders post to share excitement; people with severe side effects post to warn others. The silent majority who had a neutral or mildly positive experience rarely write anything. The RECONNECT responder rate of ~25% is probably a more reliable signal than the distribution of online sentiment [1]. Clinicians at the Endocrine Society recommend framing this to patients before prescribing: roughly three in four women will not meet the clinical responder threshold.

Switching From Flibanserin to Bremelanotide

Switching from flibanserin (Addyi) to bremelanotide is the most common transition seen in clinical practice. Flibanserin carries a black-box warning about CNS depression when combined with alcohol, a restriction many patients find unworkable. Bremelanotide has no alcohol interaction [2].

No Pharmacologic Washout Is Required

Flibanserin has a half-life of approximately 11 hours per the Addyi FDA label [4]. A 48-hour stopping period before the first bremelanotide dose is standard clinical practice, though no randomized data specifically address this interval. The pharmacokinetic profiles do not suggest a harmful interaction if both are briefly overlapping, but there is no reason to overlap them since bremelanotide is on-demand rather than daily.

Practical Steps for the Switch

Patients switching from flibanserin typically:

1. Stop flibanserin on day 1.
2. Wait 48 hours before the first bremelanotide injection.
3. Inject the 1.75 mg auto-injector into the abdomen or thigh 45 minutes before activity.
4. Evaluate after at least four to eight uses, as single-trial assessments are unreliable.

The FSDS-DAO questionnaire is the validated instrument clinicians use to track response; patients can complete it monthly during the trial period [5]. A drop of at least 4 points on the 13-item FSDS-DAO is the threshold considered clinically meaningful based on RECONNECT anchor analyses [1].

Switching From Bremelanotide to Flibanserin

Patients switching in the other direction (most often because of bremelanotide nausea or the inconvenience of injection) face a different set of considerations.

Stopping Bremelanotide

Bremelanotide has no discontinuation syndrome. The drug is metabolized and cleared within 12 hours; no taper is needed [2]. Flibanserin can begin the day after the last bremelanotide dose.

Starting Flibanserin: What Patients Should Know

Flibanserin requires 8 weeks of consistent nightly dosing before a meaningful efficacy assessment per the Addyi prescribing information [4]. Patients switching from bremelanotide because of inadequate efficacy should understand this timeline. The VIOLET trial (N=1,672) found that flibanserin 100 mg nightly increased satisfying sexual events by 0.5-1.0 per month versus placebo at 24 weeks [6]. That effect size is also modest, and patients should not expect a dramatic response from flibanserin after failing bremelanotide. Both drugs act centrally but through different pathways, so non-response to one does not predict non-response to the other, and vice versa.

Alcohol and CNS Depression Counseling

The flibanserin label's REMS program (Risk Evaluation and Mitigation Strategy) requires prescribers to counsel patients on the alcohol prohibition [4]. This counseling is sometimes missed when flibanserin is prescribed as a second-line agent after bremelanotide, because the prescriber assumes the patient already understands HSDD pharmacotherapy. A fresh review of the alcohol restriction is warranted at every switch.

Bremelanotide Side Effect Profile in Depth

Managing the side effect burden is the central clinical challenge with bremelanotide. The 40% nausea rate [1] is not uniformly distributed across administrations. Many patients report that nausea is worst with the first injection and diminishes with subsequent doses, a pattern consistent with MC4R desensitization observed in preclinical models [3].

Nausea Management Strategies

Three strategies appear in clinical practice:

• Pre-treatment antiemetics. Taking ondansetron 4 mg orally 30 minutes before the bremelanotide injection is common, though no randomized trial has evaluated this combination. The FDA label does not specifically endorse antiemetic pre-treatment but does not prohibit it [2].
• Dose timing. Injecting 60-75 minutes before activity rather than 45 minutes may allow the peak nausea window to pass before the intended experience begins.
• Small meals. Several patient forums recommend avoiding large meals within 2 hours of injection; the pharmacokinetic basis for this is not established in published literature, but the practice is low-risk.

Blood Pressure Considerations

The transient blood pressure increase (mean approximately 1.7 mmHg systolic, 1.1 mmHg diastolic) peaks at about 1 hour post-dose and resolves within 12 hours [2]. For most healthy premenopausal women, this is clinically insignificant. Women with Stage 2 hypertension (systolic >160 mmHg) or known cardiovascular disease should not use bremelanotide per the FDA label [2]. The American Heart Association's 2018 blood pressure guidelines define Stage 1 hypertension as systolic 130-139 mmHg; patients in this range warrant a shared decision-making conversation before prescribing [7].

Hyperpigmentation

Focal hyperpigmentation of the face, gums, and breasts was observed in approximately 1% of RECONNECT participants but at higher rates in patients who used bremelanotide more than the labeled maximum frequency [1]. The FDA label states: "Bremelanotide may cause generalized increased skin pigmentation with long-term use. The long-term outcomes of this skin pigmentation are unknown" [2]. Patients should be counseled to use the drug as labeled, no more than once per 24 hours, and to report any skin changes promptly.

Who Responds to Bremelanotide? Predictors From RECONNECT

Not every premenopausal woman with HSDD is equally likely to respond. RECONNECT post-hoc analyses [1] and the broader melanocortin receptor literature suggest several patterns.

Relationship Context and Psychological Readiness

RECONNECT enrolled women in stable relationships of at least six months. HSDD with a significant relationship-conflict component is unlikely to respond to any pharmacologic agent. The American College of Obstetricians and Gynecologists Practice Bulletin on HSDD recommends that clinicians screen for relationship distress before prescribing either approved HSDD agent [8]. Bremelanotide is not a substitute for couples therapy when the underlying driver is interpersonal.

Hormone Status

Bremelanotide is approved only for premenopausal women. Post-hoc RECONNECT analyses did not identify a hormone subgroup with clearly superior response, but testosterone levels were not measured systematically. Women with low testosterone (defined as below the lower quartile of the premenopausal reference range by some expert guidelines) may benefit from addressing androgen status first; the Endocrine Society's 2019 guideline on female androgen insufficiency does not endorse routine testosterone therapy for HSDD but acknowledges emerging evidence [9].

Prior Treatment History

Women who failed flibanserin due to tolerability (primarily CNS side effects like somnolence and dizziness) rather than lack of efficacy appear to represent a reasonable target population for bremelanotide, based on the mechanistic differences between the two drugs. The converse is also plausible: women who tolerated flibanserin well but saw no desire benefit may respond better to bremelanotide's on-demand central agonism, though no head-to-head trial has tested this hypothesis.

Cost, Insurance, and Access

Bremelanotide carries a list price of approximately $900-$1,000 per kit (four auto-injectors) without insurance. Most commercial health plans do not cover it as of 2025, treating HSDD pharmacotherapy as a lifestyle indication. ACOG's 2019 guidance explicitly notes that access disparities for HSDD treatments are a patient advocacy concern [8].

The manufacturer (Palatin Technologies/AMAG Pharmaceuticals, now part of Cosette Pharmaceuticals) offers a savings card reducing out-of-pocket costs for commercially insured patients who do qualify for coverage, but uninsured patients have limited options beyond manufacturer assistance programs.

Compounded bremelanotide is available through some telehealth platforms at lower cost, but the FDA has not evaluated compounded formulations for safety or efficacy. The FDA's guidance on compounding does not endorse compounded versions of FDA-approved drugs as interchangeable [10].

A Clinical Switching Decision Framework

The table below summarizes the key decision points clinicians and patients face when choosing between or switching between the two FDA-approved HSDD agents.

| Factor | Bremelanotide (Vyleesi) | Flibanserin (Addyi) | |---|---|---| | Dosing schedule | On-demand, 45 min before activity | Daily, every night at bedtime | | Alcohol restriction | None | Strict; black-box warning | | Primary side effect | Nausea (40%), flushing (20%) | Somnolence, dizziness | | Onset of efficacy | Single dose; assess after 4-8 uses | 8 weeks of daily dosing | | Cardiovascular contraindication | Yes (transient BP rise) | No (but CNS/alcohol interaction) | | Washout before switching | 48 h (flibanserin clearance) | Not required (bremelanotide clears in 12 h) | | Responder rate vs placebo | ~25% vs ~17% [1] | ~10% increase in satisfying events vs placebo [6] |

What Clinicians Say About Bremelanotide in Practice

The sexual medicine community has been measured in its enthusiasm. Dr. Sheryl Kingsberg, a clinical psychologist and HSDD researcher who served as a principal investigator on RECONNECT, stated in a 2019 interview published by the Endocrine Society: "Bremelanotide offers premenopausal women a choice that was not previously available. The on-demand nature addresses a real barrier with daily therapy." [11]

The North American Menopause Society (NAMS) 2022 position statement on sexual health notes that both approved HSDD agents show "modest but statistically significant improvements in desire and sexual distress" and that shared decision-making regarding side effect profiles should guide agent selection [12].